라벨 프리 어레이 시스템 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Label-free Array Systems Market Growth & Trends:

The global label-free array systems market size is anticipated to reach USD 818.41 million by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 7.7% from 2025 to 2030. The market is expected to witness substantial growth during the forecast period. This growth is attributed to the increasing fundraising by biotech startups for developing innovative products. Additionally, rising awareness of personalized diagnostic and therapeutic treatments in emerging markets is also a contributing factor to the growth of the label-free array system.

Label-free array systems are analytical technologies that are used to detect and quantify biomolecules in complex samples without the use of fluorescent or radioactive labels. These systems rely on the principle of Surface Plasmon resonance (SPR) which allows the detection of changes in the reflected light and quantifying the binding of biomolecules to the surface of the array.

One of the main advantages of label-free array systems is that they do not require the use of hazardous or expensive labeling agents, making them a safer and more cost-effective alternative to traditional labeling methods. Additionally, because they do not rely on fluorescence or radioactivity, label-free array systems can be used to study biomolecule interactions in real time, providing dynamic and quantitative information about the binding kinetics and affinity of the interacting molecules.

Similarly, companies are also growing the application scope for label-free array systems. The technique offers a quantitative analysis of interactions without altering the individual components of the array. According to Sartorius, the emerging application for label-free array systems are Biologics & Small Molecules Research, characterization of kinetic, bioprocessing, COVID-19 research, GxP applications, lead optimization and selection, titer and impurity testing, and target ID and validation.

Additionally, the advancement of material science along with computational design and nanofabrication have resulted in the development of label-free protein microarray approaches. These approaches have showcased significant results in protein profiling, drug discovery, biomarker screening, and drug target identification. Hence, the development of new technologies is expected to enhance the growth of label-free array systems in the market.

Furthermore, North America has captured the majority of the market share. The significant share is due to the well-established healthcare facilities in this region along with increasing investment in the R&D sector. The rising awareness amongst healthcare professionals and patients of early detection and treatment of chronic disease speeds up the diagnostic capabilities in this region and surges the growth of the product.

Label-free Array Systems Market Report Highlights:

• By type, surface plasmon resonance is anticipated to capture the majority of the label-free array system market share in 2024. Owing to the increasing R&D investment in biomedical research by companies is expected to support the growth of label-free array systems during the forecast period.
• By application, drug discovery is considered the key application with the largest market share in 2024, and this trend is likely to be maintained over the forecast period. This growth can be attributed to the increasing use of personalized medicines in developing countries.
• By end-users, the academic and research institutions segment is estimated to witness significant growth during the forecast period. The growth is attributed to the increasing grants and financial assistance from the government and companies.
• North America has established a substantial position in the regional market with 47.20% of the overall market share. The increasing use of personalized medicines and high R&D expenditure are encouraging companies to undertake product development in the region.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Information Procurement
• 1.2. Information or Data Analysis
• 1.3. Market Scope & Segment Definition
• 1.4. Market Model
  • 1.4.1. Market Study, By Company Market Share
  • 1.4.2. Regional Analysis

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
• 3.5. Market Restraint Analysis
• 3.6. Penetration and Growth Prospect Mapping 2022
• 3.7. Business Environment Analysis
  • 3.7.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.7.2. Porter's Five Forces Analysis
• 3.8. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

• 4.1. Label-free Array Systems Market: Type Movement Analysis
• 4.2. Surface Plasmon Resonance
  • 4.2.1. Surface Plasmon Resonance Market, 2018 - 2030 (USD Million)
• 4.3. Bio-layer Interferometry
  • 4.3.1. Bio-layer Interferometry Market, 2018 - 2030 (USD Million)
• 4.4. Cellular Dielectric Spectroscopy
  • 4.4.1. Cellular Dielectric Spectroscopy Market, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

• 5.1. Label-free Array Systems Market: Application Movement Analysis
• 5.2. Drug Discovery
  • 5.2.1. Drug Discovery Market, 2018 - 2030 (USD Million)
• 5.3. Protein Interface Analysis
  • 5.3.1. Protein Interface Analysis Market, 2018 - 2030 (USD Million)
• 5.4. Antibody Characterization
  • 5.4.1. Antibody Characterization Market, 2018 - 2030 (USD Million)
• 5.5. Others
  • 5.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. End-use Business Analysis

• 6.1. Label-free Array Systems Market: End-use Movement Analysis
• 6.2. Pharmaceutical & Biotechnology Companies
  • 6.2.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
• 6.3. Academic & Research Institutes
  • 6.3.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
• 6.4. CRO
  • 6.4.1. CRO Market, 2018 - 2030 (USD Million)
• 6.5. Others
  • 6.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. Label-free Array Systems Market Share By Region, 2024 & 2030
• 7.2. North America
  • 7.2.1. SWOT Analysis
  • 7.2.2. North America Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.2.3. U.S.
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Target Disease Prevalence
    • 7.2.3.3. Competitive Scenario
    • 7.2.3.4. Regulatory Framework
    • 7.2.3.5. Reimbursement Scenario
    • 7.2.3.6. U.S. Label-free array systems Market, 2018 - 2030 (USD MILLION)
  • 7.2.4. Canada
    • 7.2.4.1. Key Country Dynamics
    • 7.2.4.2. Target Disease Prevalence
    • 7.2.4.3. Competitive Scenario
    • 7.2.4.4. Regulatory Framework
    • 7.2.4.5. Reimbursement Scenario
    • 7.2.4.6. Canada Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.2.5. Mexico
    • 7.2.5.1. Key Country Dynamics
    • 7.2.5.2. Target Disease Prevalence
    • 7.2.5.3. Competitive Scenario
    • 7.2.5.4. Regulatory Framework
    • 7.2.5.5. Reimbursement Scenario
    • 7.2.5.6. Mexico Label-free array systems Market, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. SWOT Analysis
  • 7.3.2. Europe Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Target Disease Prevalence
    • 7.3.3.3. Competitive Scenario
    • 7.3.3.4. Regulatory Framework
    • 7.3.3.5. Reimbursement Scenario
    • 7.3.3.6. Germany Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.3.4. UK
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Target Disease Prevalence
    • 7.3.4.3. Competitive Scenario
    • 7.3.4.4. Regulatory Framework
    • 7.3.4.5. Reimbursement Scenario
    • 7.3.4.6. UK Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.3.5. France
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Target Disease Prevalence
    • 7.3.5.3. Competitive Scenario
    • 7.3.5.4. Regulatory Framework
    • 7.3.5.5. Reimbursement Scenario
    • 7.3.5.6. France Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.3.6. Italy
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Target Disease Prevalence
    • 7.3.6.3. Competitive Scenario
    • 7.3.6.4. Regulatory Framework
    • 7.3.6.5. Reimbursement Scenario
    • 7.3.6.6. Italy Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.3.7. Spain
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Target Disease Prevalence
    • 7.3.7.3. Competitive Scenario
    • 7.3.7.4. Regulatory Framework
    • 7.3.7.5. Reimbursement Scenario
    • 7.3.7.6. Spain Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.3.8. Denmark
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Target Disease Prevalence
    • 7.3.8.3. Competitive Scenario
    • 7.3.8.4. Regulatory Framework
    • 7.3.8.5. Reimbursement Scenario
    • 7.3.8.6. Denmark Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.3.9. Sweden
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Target Disease Prevalence
    • 7.3.9.3. Competitive Scenario
    • 7.3.9.4. Regulatory Framework
    • 7.3.9.5. Reimbursement Scenario
    • 7.3.9.6. Sweden Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.3.10. Norway
    • 7.3.10.1. Key Country Dynamics
    • 7.3.10.2. Target Disease Prevalence
    • 7.3.10.3. Competitive Scenario
    • 7.3.10.4. Regulatory Framework
    • 7.3.10.5. Reimbursement Scenario
    • 7.3.10.6. Norway Label-free array systems Market, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. SWOT Analysis
  • 7.4.2. Asia Pacific Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.4.3. Japan
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Competitive Scenario
    • 7.4.3.4. Regulatory Framework
    • 7.4.3.5. Reimbursement Scenario
    • 7.4.3.6. Japan Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.4.4. China
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Competitive Scenario
    • 7.4.4.4. Regulatory Framework
    • 7.4.4.5. Reimbursement Scenario
    • 7.4.4.6. China Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.4.5. India
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Target Disease Prevalence
    • 7.4.5.3. Competitive Scenario
    • 7.4.5.4. Regulatory Framework
    • 7.4.5.5. Reimbursement Scenario
    • 7.4.5.6. India Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.4.6. South Korea
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Target Disease Prevalence
    • 7.4.6.3. Competitive Scenario
    • 7.4.6.4. Regulatory Framework
    • 7.4.6.5. Reimbursement Scenario
    • 7.4.6.6. South Korea Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.4.7. Australia
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Target Disease Prevalence
    • 7.4.7.3. Competitive Scenario
    • 7.4.7.4. Regulatory Framework
    • 7.4.7.5. Reimbursement Scenario
    • 7.4.7.6. Australia Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.4.8. Thailand
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Target Disease Prevalence
    • 7.4.8.3. Competitive Scenario
    • 7.4.8.4. Regulatory Framework
    • 7.4.8.5. Reimbursement Scenario
    • 7.4.8.6. Thailand Label-free array systems Market, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. SWOT Analysis
  • 7.5.2. Latin America Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.5.3. Brazil
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Competitive Scenario
    • 7.5.3.4. Regulatory Framework
    • 7.5.3.5. Reimbursement Scenario
    • 7.5.3.6. Brazil Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.5.4. Argentina
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Competitive Scenario
    • 7.5.4.4. Regulatory Framework
    • 7.5.4.5. Reimbursement Scenario
    • 7.5.4.6. Argentina Label-free array systems Market, 2018 - 2030 (USD Million)
• 7.6. MEA
  • 7.6.1. SWOT Analysis
  • 7.6.2. MEA Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.6.3. South Africa
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Competitive Scenario
    • 7.6.3.4. Regulatory Framework
    • 7.6.3.5. Reimbursement Scenario
    • 7.6.3.6. South Africa Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.6.4. Saudi Arabia
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Competitive Scenario
    • 7.6.4.4. Regulatory Framework
    • 7.6.4.5. Reimbursement Scenario
    • 7.6.4.6. Saudi Arabia Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.6.5. UAE
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Competitive Scenario
    • 7.6.5.4. Regulatory Framework
    • 7.6.5.5. Reimbursement Scenario
    • 7.6.5.6. UAE Label-free array systems Market, 2018 - 2030 (USD Million)
  • 7.6.6. Kuwait
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Target Disease Prevalence
    • 7.6.6.3. Competitive Scenario
    • 7.6.6.4. Regulatory Framework
    • 7.6.6.5. Reimbursement Scenario
    • 7.6.6.6. Kuwait Label-free array systems Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Share Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Illumina, Inc.,
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.1.3. Collection Site Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Thermo Fisher Scientific, Inc.
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.2.3. Collection Site Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Agilent Technologies, Inc.
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.3.3. Collection Site Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. PerkinElmer, Inc.
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.4.3. Collection Site Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Merck KGaA
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.5.3. Collection Site Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Danaher Corporation
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.6.3. Collection Site Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Bio-Rad Laboratories, Inc.
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.7.3. Collection Site Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. F. Hoffmann-La Roche AG
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.8.3. Collection Site Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Becton, Dickinson and Company
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.9.3. Collection Site Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Sartorius AG.
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.10.3. Collection Site Benchmarking
    • 8.4.10.4. Strategic Initiatives